![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, May 18, 2007 4:14:25 PM
I wouldn't expect this to occur. Telbivudine shares the same flaw as entecavir in this regard -- the same mutations that can confer resistance to lamivudine also can result in resistance to these two -- but adefovir / tenofovir have distinct resistance profiles that make them better candidates for follow-on or combos with lam and the others.
New resistance mutations are discovered occasionally so this is a somewhat fluid model , but I believe it's the one that guides treatment decisions currently.
The other advantage that entecavir has is that it's been demonstrated that several mutations are required for "true" resistance , which is why resistance in lam-refractory pts. builds gradually over years. I'm not sure to what extent compensatory mutations are required after the initial resistance mutation to telbivudine before "true" resistance arises , or whether the single mutations are sufficient.
The extra mutation steps are a big deal because they provide a margin of safety. The danger with these patients is in development of resistance that quickly leads to fuminant hepatitis and , often , death. This is less likely to occur suddenly with the higher genetic barrier of multiple mutations.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM